Business Context and Reporting Period
This Form 8-K Current Report was filed by Corbus Pharmaceuticals Holdings, Inc. (CRBP) on September 20, 2022. The filing primarily addresses corporate governance changes, specifically the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel appointments and does not contain financial statements or operational metrics.
Material Changes
The material change reported is the appointment of Anne Altmeyer, Ph.D., MBA, MPH, to the Board of Directors, effective September 20, 2022. Dr. Altmeyer brings extensive experience in biotechnology business development and leadership, having previously served as CEO of TigaTx, Inc., and held senior roles at Sigilon Therapeutics, Adicet Bio, Baxalta, Novartis, and Merck.
Compensation and Governance Details
- Compensation: Dr. Altmeyer will receive an initial option grant to purchase 159,200 shares of common stock, an annual cash retainer of $40,000 (pro-rated for the current year), and an annual stock option grant.
- Indemnification: The Company entered into a standard indemnification agreement with Dr. Altmeyer, covering expenses, judgments, and penalties incurred in connection with her services as a director.
- Disclosure: A press release regarding this appointment was issued on September 26, 2022, under Regulation FD.
Investor Verification Checklist
- Verify the exact number of shares (159,200) included in the initial option grant and the exercise price, which is not detailed in this summary.
- Review the full text of the Indemnification Agreement (Exhibit 10.15 referenced) to understand specific limitations and advancement of expense terms.
- Confirm the impact of this appointment on the Board's composition and committee assignments, which are not specified in this filing.
- Check subsequent filings for any financial updates, as this 8-K contains no financial data.